Literature DB >> 26973244

Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.

F Laugier1,2, J Delyon1,2, J André1,2, A Bensussan1,2, N Dumaz1,2.   

Abstract

KIT mutations are frequent in acral, mucosal and chronic sun-damage (CSD) melanoma, but little is known about the mechanisms driving the transformation of KIT-mutated melanocytes into melanoma cells. We showed that exposition of melanocytes harboring the (L576P)KIT mutation to a hypoxic environment induced their transformation into malignant cells. Transformed (L576P)KIT melanocytes showed downregulation of MITF expression characteristic of melanoma initiating cells (MICs). In agreement, these cells were able to form spheres in neural crest cell medium and low-adherence conditions, also a characteristic of MICs. Downregulation of MITF by RNA interference induced transformation of KIT-mutated melanocytes in normoxia and acquisition of a MIC phenotype by these cells. Hence, low level of MITF cooperates with oncogenic KIT to transform melanocytes. Activation of the cAMP pathway in transformed (L576P)KIT melanocytes stimulated MITF expression, and reduced cellular proliferation and sphere formation. These findings highlight the essential role of MITF in revealing the oncogenic activity of KIT in melanocytes and suggest that the cAMP pathway is a therapeutic target in KIT-mutated melanoma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26973244     DOI: 10.1038/onc.2016.39

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  39 in total

1.  Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.

Authors:  Y Cheli; S Giuliano; S Guiliano; T Botton; S Rocchi; V Hofman; P Hofman; P Bahadoran; C Bertolotto; R Ballotti
Journal:  Oncogene       Date:  2011-01-31       Impact factor: 9.867

Review 2.  Signal transduction via the stem cell factor receptor/c-Kit.

Authors:  L Rönnstrand
Journal:  Cell Mol Life Sci       Date:  2004-10       Impact factor: 9.261

3.  Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding.

Authors:  Sydney M Evans; Amy E Schrlau; Ara A Chalian; Paul Zhang; Cameron J Koch
Journal:  J Invest Dermatol       Date:  2006-06-29       Impact factor: 8.551

4.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  KIT as a therapeutic target in metastatic melanoma.

Authors:  Richard D Carvajal; Cristina R Antonescu; Jedd D Wolchok; Paul B Chapman; Ruth-Ann Roman; Jerrold Teitcher; Katherine S Panageas; Klaus J Busam; Bartosz Chmielowski; Jose Lutzky; Anna C Pavlick; Anne Fusco; Lauren Cane; Naoko Takebe; Swapna Vemula; Nancy Bouvier; Boris C Bastian; Gary K Schwartz
Journal:  JAMA       Date:  2011-06-08       Impact factor: 56.272

6.  The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.

Authors:  Ruixia Liang; Andrea R Wallace; Dirk Schadendorf; Brian P Rubin
Journal:  Pigment Cell Melanoma Res       Date:  2011-06-10       Impact factor: 4.693

7.  A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth.

Authors:  D C Bennett; P J Cooper; I R Hart
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

8.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

9.  The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.

Authors:  J R Todd; L L Scurr; T M Becker; R F Kefford; H Rizos
Journal:  Oncogene       Date:  2012-12-17       Impact factor: 9.867

10.  Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.

Authors:  Erika von Euw; Mohammad Atefi; Narsis Attar; Connie Chu; Sybil Zachariah; Barry L Burgess; Stephen Mok; Charles Ng; Deborah Jl Wong; Bartosz Chmielowski; David I Lichter; Richard C Koya; Tara A McCannel; Elena Izmailova; Antoni Ribas
Journal:  Mol Cancer       Date:  2012-04-19       Impact factor: 27.401

View more
  2 in total

1.  Critical role of glioma-associated oncogene homolog 1 in maintaining invasive and mesenchymal-like properties of melanoma cells.

Authors:  I Ketut Gunarta; Rong Li; Ryota Nakazato; Ryusuke Suzuki; Jambaldorj Boldbaatar; Takeshi Suzuki; Katsuji Yoshioka
Journal:  Cancer Sci       Date:  2017-07-11       Impact factor: 6.716

Review 2.  Hypoxia and Extracellular Acidification as Drivers of Melanoma Progression and Drug Resistance.

Authors:  Ewelina Dratkiewicz; Aleksandra Simiczyjew; Justyna Mazurkiewicz; Marcin Ziętek; Rafał Matkowski; Dorota Nowak
Journal:  Cells       Date:  2021-04-09       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.